未经证实:非结核分枝杆菌(NTM)病是世界范围内一种重要的感染性疾病。异种分枝杆菌(M.xenopi)是一种常见的NTM。由于M.xenopi引起的肺外感染,尤其是脊柱感染,是罕见的,但缺乏研究被认为是在此类患者中实施NTM控制的制约因素。本文的目的是描述一例脊椎盘炎,回顾已发表的关于异种分枝杆菌脊柱感染病例的文献,总结诱发因素,诊断,和治疗感染。
未经证实:1例系统性红斑狼疮(SLE)患者由异种结核分枝杆菌引起脊柱盘炎。研究是使用PubMed进行的,ScienceDirect,Embase,Wiley在线图书馆,和Scopus数据库使用以下搜索词:“异种分枝杆菌”,\"椎骨\",\"脊柱\",“脊椎盘炎”,\"感染\",和“骨髓炎”。
UNASSIGNED:我们检索了2022年8月之前发布的14例病例。感染的危险因素为医源性感染(3/14,21.43%),SLE(4/14,28.57%),艾滋病(4/14,28.57%),和免疫能力,无任何合并症(3/14,21.43%)。最常见的感染部位为胸椎(10/14,71.43%)和腰椎(4/14,28.57%)。共分离出14例,通过分枝杆菌培养从蟾蜍中鉴定为异种分枝杆菌。鉴定时间为55.00±7.55天(目前报道的宏基因组下一代测序(mNGS)鉴定时间仅为2天)。所有患者均接受抗生素治疗,治疗时间为13.18±2.13个月。以克拉霉素为基础的治疗有较高的改善率(5/6,83.33%)。对5例患者进行了手术干预。只有1例患者在手术治疗后没有任何改善。
未经批准:M人类的异种脊柱感染表现为不典型的临床症状。mNGS识别可能是一个不错的选择。在患有脊髓感染的免疫功能低下患者中可以考虑使用异种分枝杆菌。我们建议使用含克拉霉素的方案,并延长治疗时间以确保有效性。
UNASSIGNED: Nontuberculous mycobacteria (NTM) disease is an important infection disease throughout the world. Mycobacterium xenopi (M. xenopi) is a common NTM. Extrapulmonary infections due to M. xenopi, particularly spine infections, are a rare occurrence, but lack of research is cited as a constraint for implementing NTM control in such patients. The purposes of this paper are to describe a
case of spondylodiscitis, to review the published literature on cases of M. xenopi spine infections, and to summarize the predisposing factors, diagnosis, and treatment of infection.
UNASSIGNED: A
case of spondylodiscitis was caused by M. xenopi in a patient with systemic lupus erythematosus (SLE). Research was conducted using the PubMed, ScienceDirect, Embase, Wiley Online Library, and Scopus databases using the following search terms: \"Mycobacterium xenopi\", \"vertebral\", \"spinal\", \"spondylodiscitis\", \"infection\", and \"osteomyelitis\".
UNASSIGNED: We retrieved 14 cases published before August 2022. The risk factors for infection were iatrogenic infections (3/14, 21.43%), SLE (4/14, 28.57%), AIDS (4/14, 28.57%), and immunocompetence without any comorbidities (3/14, 21.43%). The most common sites of infection were thoracic vertebrae (10/14, 71.43%) and lumbar vertebrae (4/14, 28.57%). A total of 14 cases were isolated and identified as M. xenopi from a toad by mycobacterial culture. The identification time was 55.00 ± 7.55 days (the present report identification time of metagenomic next generation sequencing (mNGS) was only 2 days). All patients were treated with antibiotic therapy, and the duration of treatment was 13.18 ± 2.13 months. Clarithromycin-based therapy showed a higher improvement rate (5/6, 83.33%). Surgical intervention was performed in 5 patients. Only 1 patient did not show any improvement after surgical treatment.
UNASSIGNED: M. xenopi spine infection in humans presents with atypical clinical symptoms. mNGS identification may be a good choice. M. xenopi may be considered in immunocompromised patients with spinal infection. We recommend a clarithromycin-containing regimen and prolonging the duration of treatment to ensure effectiveness.